OSI Systems, NVE, Biodexa Pharmaceuticals, Clene, Virpax Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies engaged in the research, development and commercialization of materials and devices engineered at the nanoscale (typically 1–100 nanometers). These firms apply nanoscale science across industries—such as electronics, medicine, energy and materials—to create products with novel properties. Investing in nanotechnology stocks provides exposure to cutting-edge innovation but can carry higher volatility due to the emerging nature of the technology. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.
OSI Systems (OSIS)
OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.
NASDAQ:OSIS traded down $1.24 on Friday, hitting $227.44. 115,768 shares of the company's stock were exchanged, compared to its average volume of 193,184. The firm has a 50-day moving average price of $204.23 and a 200-day moving average price of $188.67. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.88 and a quick ratio of 1.25. OSI Systems has a 52 week low of $129.18 and a 52 week high of $233.80. The company has a market cap of $3.82 billion, a P/E ratio of 29.27, a price-to-earnings-growth ratio of 1.81 and a beta of 1.28.
Read Our Latest Research Report on OSIS
NVE (NVEC)
NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.
NASDAQ:NVEC traded down $1.41 on Friday, hitting $71.75. 26,867 shares of the company's stock were exchanged, compared to its average volume of 22,803. The firm has a 50-day moving average price of $62.75 and a 200-day moving average price of $71.22. NVE has a 52 week low of $51.50 and a 52 week high of $89.98. The company has a market cap of $347.05 million, a P/E ratio of 23.15 and a beta of 1.09.
Read Our Latest Research Report on NVEC
Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
NASDAQ:BDRX traded down $0.24 on Friday, hitting $1.15. 1,272,116 shares of the company's stock were exchanged, compared to its average volume of 830,184. The firm has a 50-day moving average price of $1.47 and a 200-day moving average price of $3.25. Biodexa Pharmaceuticals has a 52 week low of $1.11 and a 52 week high of $41.50.
Read Our Latest Research Report on BDRX
Clene (CLNN)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
NASDAQ:CLNN traded down $0.08 on Friday, hitting $2.37. 157,240 shares of the company's stock were exchanged, compared to its average volume of 81,472. The firm has a 50-day moving average price of $2.99 and a 200-day moving average price of $4.10. Clene has a 52 week low of $2.28 and a 52 week high of $9.20. The company has a market cap of $21.29 million, a P/E ratio of -0.45 and a beta of 0.46.
Read Our Latest Research Report on CLNN
Virpax Pharmaceuticals (VRPX)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
NASDAQ:VRPX traded up $0.01 on Friday, hitting $0.23. 24,302 shares of the company's stock were exchanged, compared to its average volume of 201,325. The firm has a 50-day moving average price of $0.58 and a 200-day moving average price of $6.10. Virpax Pharmaceuticals has a 52 week low of $0.13 and a 52 week high of $84.75.
Read Our Latest Research Report on VRPX
Clene (CLNNW)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Shares of CLNNW stock remained flat at $0.03 on Friday. The stock has a 50-day moving average of $0.03 and a 200-day moving average of $0.04. Clene has a 52-week low of $0.02 and a 52-week high of $0.08.
Read Our Latest Research Report on CLNNW
Featured Stories
Before you consider OSI Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OSI Systems wasn't on the list.
While OSI Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
